Non-Oncology Biologics and Biosimilars Market Size, Share & Trends Analysis Report By Drug Category (Monoclonal Antibody, Toxins, Fusion Proteins, Insulin, Hormones, Gene Therapy, and Others), By Application Type, By Product Type, By Region, And By Segment Forecasts, 2025-2034
Global Non-Oncology Biologics and Biosimilars Market Size is predicted to witness a 22.0% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
- Advances in biotechnology enable the development of new biological drugs with improved efficacy, safety, and patient outcomes.
- Increasing incidences of autoimmune diseases like rheumatoid arthritis, psoriasis, and multiple sclerosis drive the demand for biologics and biosimilars that offer effective treatment options.
- North America dominated the market and accounted for a global revenue share in 2024.
- The production process for biologics is complex and costly, requiring sophisticated technology, stringent quality control, and specialized facilities.
Biologics used to treat illnesses other than cancer are known as non-oncology biologics. These medicines are either directly or indirectly derived from living organisms. For inflammatory, infectious, and autoimmune diseases, various biological products are available, such as vaccinations and therapeutic proteins. The term "biosimilar" refers to a class of biologic treatments extremely similar to an already-approved biological product. Their goal is to lower healthcare costs and increase accessibility for patients. Biologics and biosimilars outside of cancer majorly influence contemporary healthcare because they treat a wide range of illnesses and ailments effectively. In contrast, biosimilars provide more affordable alternatives to essential medications, which helps to expand access to these treatments. Furthermore, the increasing number of research and development initiatives aimed at new indications and the upcoming biologic patent expiration. The pout of various formulas and ultimate revenue is funding these research endeavours.
However, the market growth is hampered by the strict regulatory and lack of awareness criteria for the safety and health of non-oncology biologics and biosimilars market and the product's inability to prevent fog in environments with dramatic temperature fluctuations or high humidity non-oncology biologics and biosimilars, Biosimilars and non-oncology biologics have a lengthy and complicated regulatory approval process due to the large amounts of clinical data needed to prove their efficacy and similarity.
Complex manufacturing procedures produce biologics and biosimilars not used in oncology. These processes are only sometimes easy to replicate exactly, which can cause variances in product consistency and quality. One challenge for manufacturers in this sector is maintaining consistent quality. Businesses across all industries felt the effects of the global COVID-19 pandemic and consequent lockdown on their bottom lines. The private healthcare sector was one area where the pandemic made a big splash. The coronavirus pandemic profoundly affected global healthcare corporations' operations, including research and development, manufacturing, and delivery of medicines. Industrial enterprises, except those that produce essential goods, have been shuttered due to the outbreak. Additionally, product supply lines have been disrupted.
Competitive Landscape
Some Major Key Players In The Non-Oncology Biologics and Biosimilars Market:
- Accord Healthcare S.L.U.
- Alvotech
- Amgen
- AYUMI Pharmaceutica
- Biocon
- Biogen
- Biosimilar Collaborations Ireland Limited
- Boeheringer Ingelheim
- Celltrion
- Cipla
- Coherus Biosciences
- Cordavis Ltd.
- Epirus Biopharmaceuticals
- Formycon AG
- Fresenius Kabi
- Glenmark Pharmaceuticals
- Hanwha Chemical
- Hetero
- Innovent Biologics
- Kyowa Hakko Kirin (Fujifilm Kyowa Kirin Biologics)
- LG Chem
- Lupin
- Mabpharm
- Merck
- Midas Pharma GmbH
- Mylan
- Nichi-Iko Pharmaceutical
- Organon & Co.
- Pfizer
- Qilu Pharma Spain S.L.
- Ranbaxy Laboratories (now Sun Pharma)
- Samsung Bioepis
- Sandoz
- Shanghai CP Guojian Pharmaceutical
- Sorrento Therapeutics (partner)
- STADA Arzneimittel AG
- Sunshine Guojian Pharmaceutical
- Synermore
- Teva
- Torrent Pharmaceuticals
- YL Biologics
- Zydus Cadila
- Other prominent players
Market Segmentation:
The global Non-Ooncology Biologics and Biosimilars Market is segmented based on drug category, application type, and product type. Based on the drug category, the market is segmented into monoclonal antibody, toxins, fusion proteins, insulin, hormones, gene therapy, and cell therapy. By application type, the market is segmented into dermatology, endocrinology, neurology, immunology, respiratory, rheumatology, ophthalmology, and others. By product type, the market is segmented into biologics and biosimilars.
Based On The Product Type, The Biologics Segment Is Accounted As A Major Contributor To The Global Non-Oncology Biologics And Biosimilars Market.
The biologics non-oncology biologics and biosimilars market is expected to lead with a major market share in 2022. Biologics can target specific disease pathways and provide tailored therapy procedures, allowing them to provide potent and specialized therapies for various ailments. The segment's commercial dominance can be attributed to its broad acceptability.
In The Region, The North American Global Non-Oncology Biologics And Biosimilars Market Holds A Significant Revenue Share.
The North American global non-oncology biologics and biosimilars market is expected to record the maximum market share in revenue in the near future. It can be attributed to the high incidence of chronic diseases, and the regulatory framework favours biosimilar approval. Biosimilars and non-oncology biologics are in high demand due to many factors, including a large ageing population and supportive reimbursement policies. In addition, Asia Pacific is estimated to grow rapidly in the global non-oncology biologics and biosimilars market because there are a lot of generic manufacturers in this area. The region's healthcare infrastructure development and increasing elderly population are two additional factors that will drive the market's growth rate.
Recent Developments:
- In March 2023, Sandoz, a division of Novartis, has entered into a Memorandum of Understanding to build a new facility in Slovenia for the production of biologics. This action was intended to address the increasing worldwide need for biosimilar medications. The Sandoz investment was anticipated to be a minimum of USD 400 million, bolstering the company's aspiration to propel the future expansion of its worldwide biosimilars portfolio. This investment in Slovenia is one of the greatest ever made by the worldwide private sector.
Non-Oncology Biologics and Biosimilars Market Report Scope
| Report Attribute | Specifications |
| Growth Rate CAGR | CAGR of 22.0% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Drug Category, Application Type, Product Type |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
| Competitive Landscape | Accord Healthcare S.L.U., Alvotech, Amgen, AYUMI Pharmaceutica, Biocon, Biogen, Biosimilar Collaborations Ireland Limited, Boehringer Ingelheim, Celltrion, Cipla, Coherus Biosciences, Cordavis Ltd., Epirus Biopharmaceuticals, Formycon AG, Fresenius Kabi, Glenmark Pharmaceuticals, Hanwha Chemical, Hetero, Innovent Biologics, Kyowa Hakko Kirin (Fujifilm Kyowa Kirin Biologics), LG Chem, Lupin, Mabpharm, Merck, Midas Pharma GmbH, Mylan, Nichi-Iko Pharmaceutical, Organon & Co., Pfizer, Qilu Pharma Spain S.L., Ranbaxy Laboratories (now Sun Pharma), Samsung Bioepis, Sandoz, Shanghai CP Guojian Pharmaceutical, Sorrento Therapeutics (partner), STADA Arzneimittel AG, Sunshine Guojian Pharmaceutical, Synermore, Teva, Torrent Pharmaceuticals, YL Biologics, Zydus Cadila, Other prominent players. |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation Of Global Non-Oncology Biologics And Biosimilars Market-
Non-Oncology Biologics And Biosimilars Market By Drug Category-
- Monoclonal Antibody
- Toxins
- Fusion Proteins
- Insulin
- Hormones
- Gene Therapy
- Others
Non-Oncology Biologics And Biosimilars Market By Application Type-
- Dermatology
- Endocrinology
- Neurology
- Immunology
- Respiratory
- Rheumatology
- Ophthalmology
- Others
Non-Oncology Biologics And Biosimilars Market By Product Type-
- Biologics
- Biosimilars
Non-Oncology Biologics And Biosimilars Market By Region-
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Non-Oncology Biologics and Biosimilars Market Size is predicted to witness a 22.0% CAGR during the forecast period for 2025-2034.
Novo Nordisk A/S, Pfizer Inc., Takeda Pharmaceuticals, BioMarin Pharmaceuticals, GSK, AstraZeneca, and Biogen.
Non-Ooncology Biologics and Biosimilars Market is segmented based on drug category, application type, and product type.
North America region is leading the Non-Oncology Biologics and Biosimilars Market.